Duration of vasomotor symptoms in middle-aged women
- 1 May 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 16 (3) , 453-457
Abstract
Objective: Vasomotor symptoms adversely affect the quality of life and functional status of most women during the menopausal transition, but little is known about how long these symptoms last. The most effective treatment, hormone therapy (HT), carries risks and benefits that depend on the timing and duration of use. In this study we sought to estimate the duration of vasomotor symptoms in a longitudinal study. Methods: We reanalyzed primary data from 438 women in the longitudinal cohort of the population-based Melbourne Women's Midlife Health Project. Two hundred and five women who had completed 13 years of follow-up were included in the analyses. The onset and cessation of vasomotor symptoms were reported, stratifying analyses according to ever use of HT. Symptom duration was calculated as the time between the first and last bothersome hot flush reported. Results: The mean (SD) duration of bothersome menopausal symptoms for women who completed 13 years of follow-up and who never used HT was estimated to be 5.2 (3.8) years (median, 4 years). If women who used HT were included, the mean (SD) duration was 5.5 (4.0) years (median, 4 years). The estimated duration of symptoms varied according to the duration of longitudinal follow-up, with a mean estimate of 3.4 years (median, 3 years) when only 8 years of follow-up data were analyzed. The only factor associated with duration of hot flushes was regular exercise-more exercise was associated with shorter symptom duration. Conclusions: The average duration of vasomotor symptoms in this sample is more than 5 years, substantially longer than had been previously reported.Keywords
This publication has 25 references indexed in Scilit:
- Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since MenopauseJAMA, 2007
- The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptomsThe American Journal of Medicine, 2005
- Short-term Menopausal Hormone Therapy for Symptom ReliefArchives of internal medicine (1960), 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral DensityThe Women's Health Initiative Randomized TrialJAMA, 2003
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal WomenJAMA, 2003
- Ethnic Differences in Use of Complementary and Alternative Medicine at Midlife: Longitudinal Results From SWAN ParticipantsAmerican Journal of Public Health, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Hormone Replacement Therapy and Cardiovascular DiseaseCirculation, 2001
- The normal menopause transitionMaturitas, 1992